* Note: Prices are in Million (M) USD.
Description:
Septerna, Inc. is a pioneering biotechnology firm dedicated to advancing transformative therapeutics through selective protein modulation. The company harnesses proprietary technologies and unparalleled scientific expertise to develop a promising pipeline of next-generation drug candidates aimed at addressing unmet medical needs across various disease areas. With a strong emphasis on research and development, Septerna is strategically positioned for growth, presenting a compelling investment opportunity for institutional investors in the rapidly evolving biopharmaceutical landscape.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $0 M
Debt : $0 M
EBITDA : $0 M
This criteria used industry in which company operates:
Sector: Life sciences
Industry: Pharmaceutical preparations
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Error: Invalid cash flow data provided.Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used company's growth potential to calculate its fair value:
Error: Invalid income data provided.Using default values for calculation.
This criteria used Company's ability to buy back its own share:
Error: Invalid balance sheet data provided.Using default values for calculation.
Based on default values, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-1.57
Trailing 12-Month Earnings Per Share (EPS): $-1.89
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-1.57
- Latest/TTM EPS: $-1.89
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Error: Invalid income data provided.Skipping ROE-based PE.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $28.36
52-Week Low: $9.11
Threshold Price (15% Above 52-Week Low): $10.48
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $1,259 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
No positive free cash flow found (TTM or annual) to compute Owners' Earnings per share.
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 8 points to above Septerna, Inc. Common Stock (SEPN) stock.
Fair Value PE 9, Industry Based PE 14, Risk-Free Anchored PE (25% MoS) 17.36. Based on these 3 values, average assigned is 13.45. The fair value of Septerna, Inc. Common Stock (SEPN) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
